DK169923B1 - 3-[[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]alkyl]-6,7,8,9-tetrahydro-2-alkyl-4H-pyrido[1,2-a]pyrimidin-4-on-forbindelser, fremgangsmåde til fremstilling deraf og antipsykotiske præparater indeholdende disse - Google Patents

3-[[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]alkyl]-6,7,8,9-tetrahydro-2-alkyl-4H-pyrido[1,2-a]pyrimidin-4-on-forbindelser, fremgangsmåde til fremstilling deraf og antipsykotiske præparater indeholdende disse Download PDF

Info

Publication number
DK169923B1
DK169923B1 DK551989A DK551989A DK169923B1 DK 169923 B1 DK169923 B1 DK 169923B1 DK 551989 A DK551989 A DK 551989A DK 551989 A DK551989 A DK 551989A DK 169923 B1 DK169923 B1 DK 169923B1
Authority
DK
Denmark
Prior art keywords
formula
compounds
alkyl
alk
parts
Prior art date
Application number
DK551989A
Other languages
Danish (da)
English (en)
Other versions
DK551989D0 (da
DK551989A (da
Inventor
Cornelus Gerardus Mari Janssen
Alfonsus Guilielmus Knaeps
Ludo Edmond Josephine Kennis
Jan Vandenberk
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of DK551989D0 publication Critical patent/DK551989D0/da
Publication of DK551989A publication Critical patent/DK551989A/da
Application granted granted Critical
Publication of DK169923B1 publication Critical patent/DK169923B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK551989A 1988-11-07 1989-11-06 3-[[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]alkyl]-6,7,8,9-tetrahydro-2-alkyl-4H-pyrido[1,2-a]pyrimidin-4-on-forbindelser, fremgangsmåde til fremstilling deraf og antipsykotiske præparater indeholdende disse DK169923B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26785788A 1988-11-07 1988-11-07
US26785788 1988-11-07

Publications (3)

Publication Number Publication Date
DK551989D0 DK551989D0 (da) 1989-11-06
DK551989A DK551989A (da) 1990-05-08
DK169923B1 true DK169923B1 (da) 1995-04-03

Family

ID=23020416

Family Applications (1)

Application Number Title Priority Date Filing Date
DK551989A DK169923B1 (da) 1988-11-07 1989-11-06 3-[[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]alkyl]-6,7,8,9-tetrahydro-2-alkyl-4H-pyrido[1,2-a]pyrimidin-4-on-forbindelser, fremgangsmåde til fremstilling deraf og antipsykotiske præparater indeholdende disse

Country Status (21)

Country Link
EP (1) EP0368388B1 (el)
JP (1) JP2758045B2 (el)
KR (1) KR0146053B1 (el)
AT (1) ATE122349T1 (el)
AU (1) AU614437B2 (el)
CA (1) CA2000786C (el)
CL (1) CL43432B (el)
CY (2) CY1926A (el)
DE (2) DE68922577T2 (el)
DK (1) DK169923B1 (el)
ES (1) ES2075036T3 (el)
FI (1) FI92201C (el)
HK (1) HK131696A (el)
IE (1) IE66370B1 (el)
IL (1) IL92208A0 (el)
LU (1) LU91362I2 (el)
NL (1) NL300298I2 (el)
NO (2) NO173015C (el)
NZ (1) NZ231062A (el)
PT (1) PT92206B (el)
ZA (1) ZA898436B (el)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9008850D0 (en) * 1990-04-19 1990-06-13 Janssen Pharmaceutica Nv Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones
JPH07502268A (ja) * 1991-11-27 1995-03-09 ノボ　ノルディスク　アクティーゼルスカブ 化学化合物、それらの製法および使用
US5378714A (en) * 1991-11-27 1995-01-03 Novo Nordisk A/S Antipsychotic piperidine derivatives
ES2050069B1 (es) * 1992-07-10 1994-12-16 Vita Invest Sa Procedimiento para la obtencion de 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-il)piperidino)etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido(1,2-a) pirimidin-4-ona.
DK60593D0 (da) * 1993-05-26 1993-05-26 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
DK60793D0 (da) * 1993-05-26 1993-05-26 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
ES2236700T3 (es) * 1993-11-19 2005-07-16 Janssen Pharmaceutica N.V. 1,2-benzazoles microencapsulados.
AU687940B2 (en) * 1993-11-23 1998-03-05 Janssen Pharmaceutica N.V. Novel 9-hydroxy-pyrido(1,2-a)pyrimidin-4-one ether derivatives
ES2085234B1 (es) * 1994-02-24 1997-01-16 Vita Invest Sa Agente activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ES2141671B1 (es) * 1997-12-26 2001-01-01 Vita Invest Sa Compuesto pirimidinico activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
AU3900499A (en) * 1998-05-18 1999-12-06 Sepracor, Inc. (+)-hydroxyrisperidone compositions and methods
WO1999059589A1 (en) * 1998-05-18 1999-11-25 Sepracor Inc. (-)-hydroxyrisperidone compositions and methods
US6342488B1 (en) 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
ES2197801B1 (es) 2002-03-05 2005-03-16 Ferrer Internacional,S.A Procedimiento de obtencion de la 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il) piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a ) pirimidin-4-ona.
KR20040025224A (ko) * 2002-09-18 2004-03-24 주식회사 대웅 2-(2-메틸-4-옥소-6,7,8,9-테트라하이드로-4Ｈ-피리도[1,2-ａ]피리미딘-3-일)아세트알데히드 및 그 제조방법
EP1560814A1 (en) 2002-11-13 2005-08-10 Synthon B.V. Process for making risperidone and intermediates therefor
ES2546268T3 (es) 2004-09-09 2015-09-22 Janssen Pharmaceutica Nv Preparación de 9-hidroxi-3-(2-hidroxietil)-2-metil-4H-pirido[1,2-a]pirimidin-4-ona y sus cristales
US20070197591A1 (en) 2005-12-12 2007-08-23 Sandra Boom Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
EP2133352A3 (en) * 2006-08-14 2010-01-13 Teva Pharmaceutical Industries Ltd. Crystal form of 9-hydroxy-risperidone (paliperidone)
EP1940834A2 (en) 2006-08-14 2008-07-09 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of 9-hydroxy-risperidone (paliperidone)
EP2133351A3 (en) * 2006-08-14 2010-01-13 Teva Pharmaceutical Industries Ltd. Crystal form of 9-hydroxy-risperidone (paliperidone)
US7820816B2 (en) 2006-08-23 2010-10-26 Teva Pharmaceutical Industries Ltd. Process for the synthesis of CMHTP and intermediates thereof
JP2009524574A (ja) * 2006-08-23 2009-07-02 テバ ファーマシューティカル インダストリーズ リミティド Ｃｍｈｔｐ及びその中間体の合成方法
WO2008087557A2 (en) * 2007-01-08 2008-07-24 Actavis Group Ptc Ehf An improved process for preparation of 9-hydroxy-3-(2-chloroethyl)- 2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one hydrochloride
DK2154138T3 (en) * 2007-04-19 2015-11-02 Youxin Li Novel compounds for the treatment of psychotic disorders, methods of preparation and uses thereof
WO2009010988A1 (en) * 2007-07-19 2009-01-22 Natco Pharma Limited An improved, industrially viable process for the preparation of high purity paliperidone
US20090036470A1 (en) * 2007-07-27 2009-02-05 Jiri Bartl Paliperidone derivatives
WO2009045489A2 (en) * 2007-10-03 2009-04-09 Teva Pharmaceutical Industries Ltd. Process for the synthesis of cmhtp, a paliperidone intermediate
US8242269B2 (en) 2007-10-09 2012-08-14 Cipla Limited Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes
US7977480B2 (en) 2007-12-10 2011-07-12 Synthon Bv Synthesis of paliperidone
AU2009227507A1 (en) * 2008-02-05 2009-09-24 Watson Pharma Private Limited An improved process for preparation of paliperidone
WO2009130710A2 (en) * 2008-04-21 2009-10-29 Glenmark Generics Limited A process for the preparation of paliperidone intermediates
EP2303877B1 (en) 2008-05-29 2017-02-15 Inke, S.A. Process to prepare paliperidone and intermediates thereof
US8481729B2 (en) 2008-06-16 2013-07-09 Msn Laboratories Limited Processes for the preparation of paliperidone
WO2010003702A1 (en) * 2008-07-11 2010-01-14 Synthon B.V. Synthesis of paliperidone
EP2318405A2 (en) 2008-07-11 2011-05-11 Synthon B.V. Paliperidone ketone
SI22856A (sl) * 2008-07-31 2010-02-26 Krka, Tovarna Zdravil, D.D., Novo Mesto Proces za pripravo paliperidona
EP2161019A1 (en) 2008-09-05 2010-03-10 KRKA, D.D., Novo Mesto Prolonged release multiparticulate pharmaceutical composition comprising paliperidone
EP2199293A1 (en) 2008-12-22 2010-06-23 Chemo Ibérica, S.A. One-step process for preparing paliperidone and its oxalate salt
EP2202234A1 (en) 2008-12-24 2010-06-30 Laboratorios Lesvi, S.L. Purification of paliperidone
SI2275423T1 (sl) 2009-07-13 2012-06-29 Krka D.D., Novo Mesto Postopek za sintezo paliperidona
WO2011018246A2 (en) 2009-08-13 2011-02-17 Synthon B.V. Controlled release paliperidone composition
EP2343296A1 (en) 2009-12-01 2011-07-13 Chemo Ibérica, S.A. A process for the purification of paliperidone
WO2011074017A1 (en) * 2009-12-17 2011-06-23 Alkem Laboratories Ltd. A novel process for the preparation of paliperidone
US8088594B2 (en) * 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
WO2012035554A1 (en) * 2010-09-14 2012-03-22 Megafine Pharma (P) Ltd. An improved process for the preparation of highly pure paliperidone
CA2818025A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
CN102153552B (zh) * 2011-03-01 2012-08-22 吉林大学 两种帕潘立酮药物共晶及其制备方法
CN102206210B (zh) * 2011-04-01 2014-07-02 常州市第四制药厂有限公司 一种6-氟-3-(4-哌啶基)-1，2-苯并异噁唑盐酸盐的生产方法
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2016205739A1 (en) 2015-06-19 2016-12-22 Belew Mekonnen Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2019162746A1 (en) * 2018-02-21 2019-08-29 Zenvision Pharma Llp Novel derivatives of paliperidone and process for the preparation thereof
CN112601749B (zh) 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
CN116003404B (zh) * 2022-12-14 2024-10-01 杭州同舟生物技术有限公司 一种利培酮人工半抗原、人工抗原及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342870A (en) * 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles

Also Published As

Publication number Publication date
IL92208A0 (en) 1990-07-26
FI92201C (fi) 1994-10-10
CY2007025I2 (el) 2009-11-04
EP0368388A2 (en) 1990-05-16
ZA898436B (en) 1991-07-31
NO894411D0 (no) 1989-11-06
FI92201B (fi) 1994-06-30
ES2075036T3 (es) 1995-10-01
NO173015C (no) 1993-10-13
CY1926A (en) 1989-10-30
CL43432B (es) 2005-06-03
CY2007025I1 (el) 2009-11-04
CA2000786C (en) 1999-01-26
DE68922577D1 (de) 1995-06-14
DE122007000081I1 (de) 2008-02-28
AU614437B2 (en) 1991-08-29
DE122007000081I2 (de) 2010-01-28
HK131696A (en) 1996-07-26
NO2007017I2 (no) 2010-01-25
AU4443689A (en) 1990-05-10
DK551989D0 (da) 1989-11-06
KR0146053B1 (ko) 1998-08-17
FI895261A0 (fi) 1989-11-06
PT92206B (pt) 1995-07-06
KR910009700A (ko) 1991-06-28
EP0368388B1 (en) 1995-05-10
JPH02191276A (ja) 1990-07-27
IE893564L (en) 1990-05-07
PT92206A (pt) 1990-05-31
NL300298I2 (nl) 2008-03-03
NO894411L (no) 1990-05-08
DE68922577T2 (de) 1995-09-28
JP2758045B2 (ja) 1998-05-25
NO2007017I1 (no) 2008-01-14
IE66370B1 (en) 1995-12-27
NO173015B (no) 1993-07-05
ATE122349T1 (de) 1995-05-15
LU91362I2 (fr) 2007-11-12
EP0368388A3 (en) 1991-07-17
DK551989A (da) 1990-05-08
NL300298I1 (nl) 2007-12-03
CA2000786A1 (en) 1990-05-07
NZ231062A (en) 1991-09-25

Similar Documents

Publication Publication Date Title
DK169923B1 (da) 3-[[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]alkyl]-6,7,8,9-tetrahydro-2-alkyl-4H-pyrido[1,2-a]pyrimidin-4-on-forbindelser, fremgangsmåde til fremstilling deraf og antipsykotiske præparater indeholdende disse
US6320048B1 (en) 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
ES2759253T3 (es) Derivados de imidazol tricíclicos condensados como moduladores de la actividad de TNF
ES2743208T3 (es) Derivados de tetrahidroimidazopiridina como moduladores de la actividad TNF
DK168537B1 (da) 1,2-benzisoxazol-3-yl- og 1,2-benzisothiazol-3-yl-derivater, en fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende sådanne derivater
CA2175372C (en) Novel 9-hydroxy-pyrido[1,2-a]pyrimidin-4-one ether derivatives
AU2011346733C1 (en) Novel fused pyridine compounds as casein kinase inhibitors
ES2752144T3 (es) Derivados de tetrahidrobencimidazol como moduladores de la actividad de TNF
KR100190297B1 (ko) 신규 2,9-이치환된-4H-피리도[1,2-a]피리미딘-4-온
EP2268638A1 (en) Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
DK175124B1 (da) 3-piperazinylbenzazolderivater, fremstilling deraf og anvendelse deraf i et antipsykotisk præparat
US5075315A (en) Antipsychotic hexahydro-2H-indeno[1,2-c]pyridine derivatives
HU223466B1 (hu) Allergia elleni imidazo[1,2a]tieno[2,3-d]azepin-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
PL177224B1 (pl) Nowy związek, pochodna imidazoazepiny, środek farmaceutyczny i sposób wytwarzania pochodnej imidazoazepiny
HRP950531A2 (en) 1,2-benzisoxazol-3-yl derivatives

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
CTFF Application for supplementary protection certificate (spc) filed

Spc suppl protection certif: CA 2007 00071

Filing date: 20071219

Expiry date: 20141106

CTFG Supplementary protection certificate (spc) issued

Free format text: PRODUCT NAME: PALIPERIDON ((PLUS MINUS)-3-{2-[4-(6-FLUOR-1,2-BENZISOXAZOL-3-YL)PIPERIDINO]ETHYL}-6,7,8,9-TETRAHYDRO-9-HYDROXY-2-METHYL-4H-PYRIDO[1,2-A]PYRIMIDIN-4-ON)

Spc suppl protection certif: CA 2007 00071

Filing date: 20071219

PUP Patent expired